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The human Alzheimer’s disease (AD) brain accumulates angiogenic markers but para-
doxically, the cerebral microvasculature is reduced around Aß plaques. Here we demonstrate
that angiogenesis is started near Aß plaques in both AD mouse models and human AD
samples. However, endothelial cells express the molecular signature of non-productive
angiogenesis (NPA) and accumulate, around Aß plaques, a tip cell marker and IB4 reactive
vascular anomalies with reduced NOTCH activity. Notably, NPA induction by endothelial loss
of presenilin, whose mutations cause familial AD and which activity has been shown to
decrease with age, produced a similar vascular phenotype in the absence of Aß pathology.
We also show that Aß plaque-associated NPA locally disassembles blood vessels, leaving
behind vascular scars, and that microglial phagocytosis contributes to the local loss of
endothelial cells. These results define the role of NPA and microglia in local blood vessel
disassembly and highlight the vascular component of presenilin loss of function in AD.
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Senile plaques are mainly composed of aggregated forms ofthe amyloid ß (Aß) peptide, which is generated by thesequential action of two proteases, the ß-secretase/BACE1
and the γ-secretase complex —whose catalytic subunit is Pre-
senilin (PSEN1 or PSEN2)— on the Aß precursor protein (APP)1.
Most of Alzheimer’s disease (AD) cases are sporadic AD (sAD),
whereas only a small percentage of patients have familiar AD
(fAD) with an earlier onset and a more aggressive clinical course2.
fAD-associated mutations, either in the APP, PSEN1, or PSEN2
loci, correlated with either higher production of toxic Aß1–42
species (APP) or a higher ratio of Aß1–42/Aß1–40 (PSEN)2. Intri-
guingly, PSEN fAD variants are loss-of-function mutations with
reduced processing of other substrates like NOTCH3,4. In sAD
cases, age is the greatest risk factor5 and associates with decreased
γ-secretase activity over NOTCH6.
NOTCH signaling is involved in many different cellular pro-
cesses, including the growing of new vessels by angiogenesis7–10
and the generation and maintenance of the blood–brain barrier
(BBB)11. Remarkably, Aß plaques accumulate angiogenic/hypoxic
markers but paradoxically cerebral microvasculature is rather
decreased (for recent reviews see refs. 12,13), specially around Aß
deposits in the human AD brain14–18 and in AD mice19–21,
suggesting an abnormal angiogenic process in the disease. Phy-
siological angiogenesis is started by the hypoxia/inflammation-
mediated induction of the vascular endothelial growth factor
(VEGF), which binds to VEGFR2 in endothelial cells22. Upon
ligand binding, VEGFR activates the extrusion of tip cells from
the capillaries by the mobilization of the extracellular matrix, loss
of the BBB, and emission of filopodia22. In turn, tip cells induce
lateral inhibition of the neighboring stalk cells, which includes
repression of VEGFR2 expression and activation of proliferation,
lumen formation, and BBB genetic program7–10. Molecularly,
lateral inhibition is mediated by the activation of Delta-like 4
(DLL4) in tip cells that, in turn, signal over NOTCH trans-
membrane receptors expressed by the adjacent cells, in a process
requiring the activity of the γ-secretase complex7–10. Even partial
inhibition of the DLL4/NOTCH pathway induces the initiation of
pathologic angiogenesis that disassembles mature blood vessels
into non-conducting tip cells, in a process termed non-productive
angiogenesis (NPA)7.
We hypothesize that a failure in lateral inhibition during
angiogenesis could explain the accumulation of angiogenic mar-
kers and the reduction in Aß plaques-associated blood vessels
observed in the human AD brain. To test our hypothesis, we first
describe that angiogenesis initiates around Aß deposits both in
the human AD brain and in an AD mouse model. Then, we show
that the molecular signature of NPA is highly enriched in AD
endothelial cells, abnormal vascular structures accumulate around
Aß plaques in two different AD mouse models using histologic
NPA markers, and the transcriptional activity of NOTCH is
reduced. We also demonstrate, in mouse models, that adult
genetic reduction of lateral inhibition in cerebral endothelial cells
is sufficient to produce similar vascular anomalies in the absence
of Aß overexpression. These abnormal vascular areas in the brain
of AD mouse models replace blood vessels forming vascular scars
(VaS). The disassembly of Aß plaque-associated blood vessels
involves microglial recruitment and phagocytosis of endothelial
cells and, again, induction of NPA is sufficient to induce vessel
phagocytosis by microglia in the absence of Aß deposition.
Results
Angiogenesis is initiated around Aß plaques in the AD brain.
The accumulation of an extracellular proteinaceous deposit (Aß
plaques) could disrupt the even distribution of cerebral capil-
laries, producing mild hypoxia (Fig. 1a). Thus, we first evaluated
if Aß plaques induce local hypoxia in normoxic AD mouse
models, using the hypoxic marker pimonidazole hydrochloride
(Hypoxyprobe-1) combined with Thioflavin-S (Thio-S) staining.
Remarkably, pimonidazole immunoreactivity localized around
Thio-S reactive (+) dense-core amyloid plaques (Fig. 1b). Inter-
estingly, our recent work has shown that Aß plaque-associated
microglia (AßAM) gene expression is characterized by a robust
hypoxia inducible factor 1 (HIF1)-mediated hypoxic response23,
confirming that Aß plaques are hypoxic. Under low oxygen levels,
the growth of new central nervous system vessels is normally
instructed by the expression of VEGF in astrocytes24 (Fig. 1a).
Several reports have shown that VEGF is upregulated in the
human AD brain25–27 and that VEGF protein localizes within Aß
plaques of AD mice28. However, whether VEGF induces angio-
genesis in this context is under debate29. Thus, we studied if Aß
plaque-associated astrocytes contribute to the local expression of
VEGF. We combined in situ hybridization (ISH) with immuno-
fluorescence for either the astrocytic marker glial fibrillary acidic
protein (GFAP) or the ionized calcium binding adaptor molecule
1 (IBA1) microglial marker, another cell type commonly asso-
ciated with Aß plaques. Vegfa mRNA expression was mainly
associated with astrocytes (Fig. 1c–e), scarcely observed in
microglial cells (Fig. 1e), and correlated with the protrusion of
filopodia from nearby vessels (Supplementary Fig. 1a), suggesting
angiogenic activity.
VEGF expression induces the conversion of endothelial cells
(phalanx cells) into tip cells that guide the formation of a new
vascular branch (Fig. 1f). To further evaluate the angiogenesis in
the AD mouse brain, we studied the expression of the integrin
αvß3 (Iαvß3), a transient marker of angiogenic cells30 required
for the stabilization of VEGFR2 upon binding to VEGF31. A
previous report described that Iαvß3+ cells accumulated in the
human AD brain32. We found that Iαvß3+ cells concentrated
around Aß plaques in comparison with wild-type (WT) and non-
Aß plaques brain areas in AD mouse models (Fig. 1g). Of note,
no differences were found between WT and distal Aß plaques
areas (Fig. 1g). Interestingly, the Iαvß3+ cells looked qualitatively
different around Aß plaques, suggesting vascular remodeling
(Fig. 1g).
To extend our observations to the human AD brain, we used
human samples obtained under tightly controlled conditions
from AD (Braak tau pathology stages IV–VI) and age-matched
Braak stage 0–I samples (Supplementary Data 1)33. Combination
of Thio-S staining with Iαvß3 immunodetection suggested a
connection between Iαvß3+ cells and Aß plaques (Fig. 2a). To
confirm the association between angiogenesis and Aß deposits,
we first localized the position of all the Iαvß3+ cells and Aß
plaques (Fig. 2b and Supplementary Fig. 1b, 655 Aß plaques and
3209 Iαvß3+ cells from five AD cases) and measured the load of
the neurofibrillary tangles, another AD hallmark, in each AD case
studied. An almost perfect direct correlation was observed
between the number of Iαvß3+ cells and Aß plaques (Fig. 2c)
and, on the contrary, no association was found between Iαvß3+
cells and tangles (Supplementary Fig. 1c). As described before32,
the number of Iαvß3+ cells in control samples was very low (55
Iαvß3+ cells from five control samples; Fig. 2c). Second, we
performed 500 simulations where the position of Aß plaques was
conserved and the location of the Iαvß3+ cells was randomly
generated in each AD case. We then measured the shortest
geodesic distance between each Iαvß3+ cell and the closest Aß
plaque in each random simulation and in the experimental cases.
Notably, in the five AD cases studied, the experimental shortest
distance between Iαvß3+ cells and Aß plaques was always
significantly smaller than in the random simulations (Fig. 2d and
Supplementary Fig. 1d) and, globally, the shortest distance
between Iαvß3+ cells and Aß plaques was also significantly
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smaller to that expected in a random distribution of Iαvß3+ cells
(Fig. 2e).
Altogether, the presence of hypoxia around Aß plaques, the
local induction of VEGF expression by astrocytes, and the
concentration of angiogenic cells near Aß plaques strongly
suggest that angiogenesis is initiated around Aß deposits in both
the human AD brain and in AD mouse models.
The angiogenesis around Aß plaques is non-productive. As











































































































Fig. 1 Angiogenesis is concentrated around Aß plaques in AD mouse models. a Working model of the angiogenesis around Aß plaques. Aß deposition
separate vessels (1) producing local hypoxia (2) and inducing angiogenic factors expression (3). b Coronal cortical sections of 14-month-old APP-PSEN1/+mice
treated with Hypoxiprobe (Pimonidazole HCl; 60mg/kg i.p.; 45min) showing hypoxia (brown, immunoperoxidase, DAB) in the vicinity of Aß plaques (green,
Thioflavin-S staining –Thio-S–). The dashed square box is shown in the rightest panel. Scale bar= 100 and 25 µm, respectively, in low and high magnification
images. c, d Vegfa is mainly expressed by astrocytes around Aß plaques in 8-month-old APP-PSEN1/+ mice. Aß plaques are indicated by a yellow asterisk.
Cortical confocal XY images stained with astrocytic (GFAP; cyan; c), Vegfa (in situ hybridization, ISH; brown), Aß (Thio-S; green), microglial (IBA1; cyan, d), and
nuclear (DAPI; blue) markers. White arrowheads indicate microglial cells without Vegfa expression and red arrowheads point to a non-microglial Vegfa-
expressing cell (d). Scale bars (c, d)= 20 µm. e Quantification of the number of astrocytes (AS) and microglia (M) expressing Vegfa mRNA per Aß plaque.
Mean ± SEM. n= 5 mice (5 Aß plaques per mice); Student’s t-test. f VEGF differentiates phalanx cells to tip cells that extrude from the vessel and stalk cells
that will produce the new capillary (4). g A cortical mouse brain area stained with angiogenic endothelial (Integrin αvß3 –Iαvß3–; red), microglial (IBA1; green),
endothelial (IB4; white), and nuclear (DAPI; blue) markers. Scale bar= 20 µm. Right graph, quantification of the Iαvß3+ cell density in 8-month-old wild-
type (WT) and APP-PSEN1/+ mice. Mean ± SEM. n= 4 WT and 5 APP-PSEN1/+ mice; ANOVA, post hoc Tukey’s test.
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accumulation of angiogenic markers coupled with reduced
number of vessel and disruption of the BBB. To investigate if
angiogenesis is halted by a failure in differentiation between tip
and stalk cells (NPA) in AD mouse models (Fig. 3a), we separated
CD31+ (an endothelial/innate immune cell marker) and CD11b-
negative (an innate immune marker) cells using fluorescence-
activated cell sorting (Supplementary Fig. 2a–c) from aged (18-
month-old) APP-PSEN1/+ and WT mice. mRNA levels of a
vascular specific marker (Cadherin 5, Cdh5) greatly exceeded the
levels of microglia, astrocyte, oligodendrocyte, and neuronal
markers (Supplementary Fig. 2d), confirming the purity of the
isolated endothelial cells. A global expression analysis was per-
formed using microarrays and the differentially expressed (DE)
genes are shown in the Supplementary Data 2. To evaluate
whether endothelial cells from an Aß-accumulating AD mouse
model could suffer NPA, we defined a gene set (GS) containing
the genes upregulated in the retina of Dll4 heterozygous mice
(Dll4+/–_Up)34, a model of NPA7–10, and estimated its con-
tribution to the DE genes between APP-PSEN1/+ and
WT endothelial cells using GS enrichment analysis (GSEA).
Notably, the Dll4+/–_Up GS was enriched at the top of the
list —and the only one with a significant FWER p value— out of
more than 800 GS analyzed (Fig. 3b, c and Supplementary
Data 3), strongly suggesting a failure of the endothelial lateral
inhibition in AD mouse models. NPA induces an increase in the
number of tip cells in the retina of mouse models7–10. From the
list of the DE genes included in the Dll4+/–_Up GS, we selec-
ted the Plasminogen activator, urokinase receptor (Plaur) gene, a
tip cell marker34, for histological validation of our molecular
studies. We combined ISH with isolectin B4 (IB4) from Griffonia
simplicifolia staining, a well-described marker of mouse mature





































































































Fig. 2 Angiogenesis is concentrated around Aß plaques in AD. a A human hippocampal brain slice stained with angiogenic endothelial (Iαvß3; red), Aß
(Thio-S; green), and nuclear (DAPI; blue) markers. Scale bar= 20 µm. Arrowheads indicate angiogenic cells and arrows signal Aß plaques. b A human
hippocampal brain slice where the position of Iαvß3+ cells (red dots) and Aß plaques (blue dots) are indicated. Scale bar= 1 mm. c Correlation between
Iαvß3+ cells and the number of Aß plaques in five AD (Braak IV–VI) cases (green dots). The number of Iαvß3+ cells is also indicated for six control (Braak
0–I) human samples (orange dots). Spearman r correlation. d Left graph, representation of the probability of the averaged shortest distance between
Iαvß3+ cells and Aß plaques in 500 random simulations (RS, blue bars) where the Aß plaques position was fixed and the Iαvß3+ cells’ location was
randomized. The red dot represents the experimental measurement. Right graph, quantification of the shortest geodesic distance between Iαvß3+ cells and
Aß plaques in an experimental (E) and in the first 10 random simulations (RS). Data are presented as mean ± SEM. n= 28 (E) and 280 (RS) Iαvß3+ cells
and 16 Aß plaques. Student’s t-test. e Quantification of the averaged shortest geodesic distance between Iαvß3+ cells and Aß plaques from experimental
(E) human brain slices and 500 random simulations (RS) of Iαvß3+ cells location. Mean ± SEM. n= 5 human samples; Student’s t-test.
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mRNA in endothelial cells was observed in WT or in regions
distal to Aß plaques in an AD mouse model (Fig. 3d). However, a
dramatic increase in Plaur mRNA expression was observed
around Aß plaques (Fig. 3d), further demonstrating that,
although the tip cell program is activated, the DLL4/NOTCH
interaction (see Fig. 3a) that limits tip cell accumulation is
affected near the Aß plaques.
IB4 is also a marker of the vascular abnormalities observed in
NPA models7–10 characterized by the accumulation of tip cells
(Fig. 3a). As expected, IB4 delineated the vessels distal to Aß plaques
(Fig. 3e and Supplementary Fig. 3a); however, IB4 recognized
abnormal structures around Aß deposits. Those structures presented
a “cotton candy”-like appearance, and emanated from well-perfused
IB4+ vessels (Evans blue —EB— angiography; Fig. 3e and
































Gene sets enriched in APP-PSEN1/+ vs WT EC
Name        NES FWER-p-val
Dll4+/–_Up       2.22   0.004
GO_MYELOID_DENDRITIC_CELL_...      1.98   0.139
GO_CELLULAR_EXTRAVASSATION         1.96   0.199
GO_REGULATION_OF_GRANULOCYTE_...   1.95   0.207
GO_REGULATION_OF_CD4_. ..          1.95   0.224
GO_ESTABLISHMENT_OF_PROTEIN_...    1.93   0.288
GO_REGULATION OF NEUTROPHIL_...    1.92   0.339
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Supplementary Fig. 3a). The IB4+ vascular anomalies were not
colocalized either with astrocytes (Supplementary Fig. 3b) or
microglial cells (Supplementary Fig. 3c), the two cell types more
commonly found in the proximity of Aß plaques. To further
evaluate the contribution of innate immune cells to the IB4+
vascular abnormalities, we examined the cerebral vasculature of an
experimental autoimmune encephalomyelitis (EAE) mouse model36
(Supplementary Fig. 3d), including 3 sham control and 12 EAE mice
distributed in three groups based on behavioral evaluation and the
time of evolution after the induction of the disease (4 onset, 4 peak,
and 4 post-peak mice; Supplementary Fig. 3e). We did not find any
IB4+ vascular anomalies, despite the strong glial activation observed
around endothelial cells (Supplementary Fig. 3, compare panel 3f—
onset—with 3g—peak; 0 IB4+ vascular abnormalities in 103
autoimmune foci examined).
In the APP-PSEN1/+ AD mouse model, the IB4+ vascular
anomalies were found in regions containing Aß plaques,
including the cortex, hippocampus, and the corpus callosum
(Fig. 3e–g and Supplementary Movie 1), covering up to 5% of the
total cortical surface (Fig. 3h) and not detected in WT mice
(Fig. 3h). Although those mice express dominant APP and PSEN1
mutations in neuronal cells (driven by the Prnp promoter37), our
molecular analysis has predicted a failure of NOTCH signaling in
endothelial cells, which involves the activity of the γ-secretase
(Fig. 3a). To discard any alteration caused by PSEN1 mutated
allele to endothelial cells, we tested whether mutant mice
expressing only the APP gene will also accumulate IB4+ vascular
anomalies. The analysis of APP751SL/+, an AD model with faster
Aß plaque deposition, revealed qualitative (Fig. 3g) and
quantitative (Fig. 3h) similar accumulation of IB4+ vascular
anomalies, excluding the possibility of endothelial expression of
the mutated form of PSEN1 as the cause of the vascular
alterations in AD mouse models, and strongly suggesting that
Aß plaques induce vascular disorganization. To quantitatively
confirm the connection between the abnormal IB4+ structures
and Aß plaques, we co-stained brain slices from Aß-depositing
AD mouse models with Thio-S and IB4+ (Fig. 3i). In the brain of
young AD mice without or with a scarce number of Aß deposits
(respectively 3-month-old and 5-month-old APP-PSEN1/+
mice), IB4+ vascular abnormalities were always colocalized with
Thio-S (Supplementary Fig. 3h). In older mice, quantification of
the area of both Aß deposits (Thio-S+) and the abnormal IB4+
structures revealed a significant positive correlation between both
parameters in the regions analyzed (Supplementary Fig. 3i, j).
So far, we have shown molecular and histological indications of
NPA. To further demonstrate the loss of NOTCH activity around
Aß plaques, we generated a new AD mouse model by crossing
APP-PSEN1/+ with a NOTCH reporter mice expressing a
fluorescent nuclear protein (Histone H2B fussed with Venus)
under the control of CBF1-binding sites38 (Fig. 3j). Upon ligand
binding, NOTCH is cleaved by several proteases at the
membrane, including a final cleavage by the γ-secretase, and
the NOTCH intracellular domain (NICD) is translocated to the
nucleus, where it binds to CBF1, recognizes CBF1-binding sites at
the DNA, and activates transcription. We first checked that the
expression of the reporter was compatible with the described
activity of NOTCH in the adult brain. We focused on the
neurogenic subventricular zone, where NOTCH expression and
activity has been reported39, and observed a clear nuclear Venus
signal lining the ventricles, validating the model. In the cortex, we
observed expression of the reporter in several cell types including
the endothelium (Fig. 3k). Quantification of the endothelial
expression of the NICD reporter showed reduced expression in
the IB4+ vascular abnormalities when compared with WT or
APP-PSEN1/+ brain areas distal to Aß plaques (Fig. 3k).
Altogether, the induction of early angiogenesis markers (VEGF
and Iαvß3+), the molecular signature of NPA in vascular cells,
the accumulation of vascular abnormalities around Aß plaques,
and the decreased activity of NICD associated with the vascular
anomalies, strongly suggest that Aß plaques are associated
with NPA.
Endothelial γ-secretase LOF induces IB4+ vascular anomalies.
Loss of function of γ-secretase has been linked both with fAD
(PSEN1 and PSEN2 mutations)2–4 and sAD (decreased NOTCH-
processing activity associated with age)6. Due to the role of the γ-
secretase in the production of Aß, many of the studies have been
focused in the loss of γ-secretase in neurons4. However, muta-
tions in PSEN1/PSEN2 will modify γ-secretase activity in all the
cells and, during aging, other cells types may also be altered by a
decrease in γ-secretase activity, and therefore, contribute to the
progression of AD. In addition, it has been proposed that the high
Fig. 3 Angiogenesis is non-productive around Aß plaques. a Working model of the angiogenesis around Aß plaques. Numeration continues from Fig. 1f.
Upper row: Non-productive angiogenesis will convert phalanx cells to non-conducting tip cells, extending local hypoxia (5). Lower row: γ-secretase activity
is involved in the lateral inhibition process that controls tip-stalk cell identity. b, c Gene set enrichment analysis (GSEA) revealed that Dll4+/–_Up GS is
highly represented in 18-month-old APP-PSEN1/+ versus WT endothelial cell differential transcriptomic (b, left panel). Right panel (b) shows the heat map
of the top 30 ranking leading edge genes included in the Dll4+/–_Up GS. Red symbolizes overexpression and blue down regulation. The table includes the
eight top-enriched GSs (c), FEWER p val (values) were two-sided and adjusted for multiple comparisons. d Cortical confocal XY images from 8-month-old
APP-PSEN1/+ and stained with endothelial (IB4; red), Plaur (ISH; brown), Aß (Thio-S; green), and nuclear (DAPI; blue) markers. Arrowheads indicate
reactive cells expressing Plaur. Scale bar= 20 µm. Right graph shows the quantification of Plaur+ cells/mm2 in WT (gray dots) and distal to Aß plaques (D;
light blue dots) and IB4+ regions (IB4+; blue dots) in the APP-PSEN1/+mouse model. Mean ± SEM. n= 4WT and 3 APP-PSEN1/+mice; ANOVA, post hoc
Tukey’s test. e Cortical confocal projection from 8- (upper row) and 12- (lower row) month-old APP-PSEN1/+mice injected with Evans Blue (EB, white) and
stained with endothelial (IB4; red) and nuclear (DAPI; blue) markers. Aß plaques are indicated with a yellow asterisk. Scale bar= 20 µm. f Full hemi-cortex
from a 10-month-old APP-PSEN1/+ mouse stained to visualize endothelial cells (IB4; red) and rendered transparent using iDISCO. Scale bar= 500 µm.
g Superimages of brain cortical sections from WT, APP-PSEN1/+, and APP751SL/+ mice stained to label endothelial cells (IB4; red). Insets show the white
square from low magnification images. Scale bar= 1 mm in low and 500 µm in high magnification images. h Quantification of the percentage of cortical
surface occupied by abnormal IB4+ staining. Mean ± SEM. n= 3 8-month-old WT and APP-PSEN1/+; and 12-month-old APP-PSEN1/+; and 6 APP751SL/+
mice; ANOVA, post hoc Tukey’s test. i Image of a cortical slice from 8-month-old APP-PSEN1/+ mice stained with endothelial (IB4; red), Aß (Thio-S;
green), and nuclear (DAPI; blue) markers. Scale bar= 100 µm. j Schematic representation of the Cp-HIST1H2BB::Venus/+ mouse model. NICD NOTCH
intracellular domain, CBF1 BS CBF1-binding sites. k Left images: coronal cortical sections from Cp-HIST1H2BB::Venus/+; APP-PSEN1/+ mice distal (left) and
proximal (right) to Aß plaques and stained with endothelial (IB4; red), and nuclear (DAPI; blue) markers. Green: Direct visualization of H2BB::Venus
fluorescence. Scale bar= 20 µm. Right graph, quantification of the number of H2BB::Venus positive endothelial cells in Cp-HIST1H2BB::Venus/+; +/+
(Control, C), Cp-HIST1H2BB::Venus/+; APP-PSEN1/+ distal (D) and IB4+ proximal (P) to Aß plaques. Mean ± SEM. n= 3 Cp-HIST1H2BB::Venus/+; +/+
and 6 Cp-HIST1H2BB::Venus/+; APP-PSEN1/+ mice; ANOVA, post hoc Tukey’s test.
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concentration of Aß1–42 around Aß plaques could inhibit γ-
secretase activity as a product of the reaction4. We therefore
investigate the consequences of reducing γ-secretase activity in adult
AD brain endothelial cells. To this end, we genetically inhibited
endothelial γ-secretase activity by injecting Psen1loxP/loxP; Psen2–/–
mice with cerebral endothelium-specific Cre recombinase-
expressing adeno-associated vectors (AAV-BR1; Fig. 4a)40. First,
we validated that the viral vector induced the deletion of the Psen1
gene in the brain. We designed a quantitative PCR (qPCR)
amplicon to detect the Psen1 excised locus (Fig. 4b) and verified
that the injected mouse induced the loss of Psen1 allele (Fig. 4b) at
two different time points after the injection of the viral vector, 19
and 60 days. Interestingly, a trend was observed to reduce the
deletion with time (19 days, 0.33 ± 0.12 versus 60 days, 0.14 ± 0.05;
Student’s t-test: p= 0.126). Second, we checked if the Psen1 gene
deletion was specific to endothelial cells. To this end, we performed
Psen1 mRNA ISH combined with IB4 immunofluorescence (Fig. 4c
and Supplementary Fig. 4a) and quantify the number of RNA foci
in the whole brain parenchyma (cortex and striatum). As expected,
no differences were found in the total number of Psen1 mRNA foci
(Supplementary Fig. 4a). Thus, we quantified the number of
endothelial Psen1 mRNA foci, observing a trend to decrease in the
striatum and significant decrease in the cortex (Fig. 4d; see below
for further discussion of this experiment).
To evaluate the vasculature of mice with endothelial loss of the
γ-secretase activity, we used several perfusion and BBB markers at
two different time points. Nineteen days after the viral injection,
no evident abnormalities were found. At 60 days, a normal brain
microvasculature was observed in mice injected with the control
vector (Fig. 4e); however, vessels were deeply altered in the brain
of mice injected with Cre-expressing AAVs (AAV-BR1-Cre;
Fig. 4e). Notably, we observed structures that were identical to the
IB4+ vascular abnormalities observed around Aß plaques
(compare Fig. 3e–i with Fig. 4e), even though the mouse model
employed did not accumulate Aß deposits. In this model, IB4+
vascular abnormalities were mainly found in the striatum and
hippocampus (Fig. 4e) and were associated with a loss in
perfusion (EB and TER119, Supplementary Fig. 4b, c), pericytes
(platelet derived growth factor receptor ß, PDGFRß; Fig. 4f), and
astrocytic end-feet (Aquaporin 4, AQP4; Fig. 4g). Interestingly,
no signs of endothelial proliferation were found using Ki67 (53
IB4+ vascular abnormalities analyzed from five mice), suggesting,
as expected, that NPA is blocking the differentiation of
endothelial cells to the proliferative stalk phenotype. As a control,
we identified proliferative (Ki67+) cells in the subgranular zone of
the hippocampus and in proliferating microglia.
Altogether, our data suggest that loss of vascular cells is
induced by the endothelial loss of function of γ-secretase, which
leaves behind IB4+ vascular abnormalities.
Vessel loss and accumulation of VaS around Aß plaques. The
loss of blood vessels associated with the IB4+ vascular abnorm-
alities were quite reminiscent of the defects observed around Aß
plaques in the human AD brain14–18 and in AD mice19–21. To
evaluate if Aß plaques-associated IB4+ vascular abnormalities
were also characterized by blood vessel loss, we analyzed perfu-
sion in APP751SL/+ using EB angiography35 and quantification of
marker of red blood cells, TER119 (Fig. 5a). Quantification of EB
signal showed a clear reduction in perfusion proximal to Aß
plaques compared with distal regions (Fig. 5a). As previous works
have reported disturbed brain blood flow12,13,26 and neutrophils
clotting of the cerebral capillaries41 in AD mouse models, we
analyzed brain vessels in WT and in distal and proximal regions
to Aß plaques in an AD mouse model using TER119 staining.
Interestingly, loss of perfusion was only observed around Aß
plaques and no significant differences were found between wild
type and distal cortical regions (Fig. 5a). To study if reduced Aß
plaques perfusion was associated with a morphologic change of
capillaries around Aß plaques, we used several markers of the
blood–brain barrier. First, we examined the distribution of
laminin—a marker of the endothelial basement membrane—
combined with IB4. As expected, both laminin and IB4 delineated
the vessels distal to Aß plaques (Fig. 5b); however, laminin
staining was reduced in the IB4+ vascular abnormalities (Fig. 5b).
We quantified the area occupied by laminin+ vessels in a 50 µm
radius from Aß plaques and inside the abnormal IB4+ area and
observed a significant reduction in two different AD mouse
models (Fig. 5b). Again, no differences were found between WT
and distal brain regions of the AD mouse models. Similar to
laminin, the expression of platelet/endothelial cell adhesion
molecule 1 (PECAM1/CD31; a tight junction marker) was
decreased around Aß deposits (Supplementary Fig. 5a) and no
changes were observed between WT and distal regions in the AD
mouse model. Pericyte number is decreased in both patients and
AD models18 and the reduction correlates with Aß deposits17.
Correspondingly, the expression of the PDGFRß was lost in the
anomalous IB4+ structures (Supplementary Fig. 5b) and, similar
to other vascular markers, no changes in PDGFRß expression
were observed between WT and distal regions in the AD mouse
model (Supplementary Fig. 5b). Finally, AQP4, a marker of
astrocytic end-feet, delineated the blood vessels in regions distal
to Aß plaques (Fig. 5c), but, as described42,43, a diffuse signal was
observed in the proximity of Aß deposits that colocalized with the
IB4+ vascular anomalies in some areas (Fig. 5c), including clearly
recognizable astrocytic end-feet (arrowheads in Fig. 5c). Quan-
tification of AQP4+ signal revealed no differences between WT
and distal regions in the AD mouse models and a significant
reduction around Aß plaques. Altogether, our results indicate that
Aß plaques are avascular areas were the vessels have been sub-
stituted by an abnormal IB4+ signal.
To localize IB4 staining at the ultrastructural level, we used
gold-based IB4 staining and electron microscopy. IB4 labeling
was mainly restricted to the extracellular space surrounding Aß
fibrils (Fig. 5d), a parenchyma that is normally invaded by
microglial and astrocytic projections. Based on their continuity
from perfused blood vessels (Figs. 3 and 4) and their accumula-
tion at the extracellular space around the Aß deposits (Fig. 5), we
termed these IB4+ anomalies vascular scars (VaS).
To evaluate the contribution of abnormal angiogenesis to the
progression of the disease, we treated an AD mouse model with
sorafenib, a drug that inhibits the intracellular activity of several
angiogenic kinases (VEGFR, PDGFR, and RAF) in endothelial
cells. Sorafenib treatment (30 mg/kg every 2 days for 1 month)
strongly reduced the accumulation of Iαvß3+ cells in the brain of
8-month-old APP751SL/+ mice (Supplementary Fig. 6a), indicat-
ing that the selected dose of Sorafenib was enough to reduce
angiogenic activity. We then examined Aß deposits using Thio-S
staining and revealed that Sorafenib presented a trend to reduce
both Aß plaque load and the mean Aß plaque area (Supplemen-
tary Fig. 6b) without altering the Aß1–40, Aß1–42, and Aß1–42/
Aß1–40 levels, as estimated by ELISA (Supplementary Fig. 6c). In
addition, analysis of pericyte coverage of blood vessels, as a
readout of vessels normalization, showed that sorafenib treatment
recovered the PDGFRß signal around Aß plaques to the
same levels observed in distal regions (Supplementary Fig. 6d).
Finally, we estimated the short-term memory using the novel
object recognition test and observed a trend to improve the
memory in sorafenib-treated mice (Supplementary Fig. 6e),
suggesting a modest recovery in cognition. Therefore, although
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Fig. 4 In adult inhibition of endothelial γ-secretase activity is sufficient to generate IB4+ vascular abnormalities. a Schematic representation of a mouse
model with adult inhibition of endothelial γ-secretase activity. Psen1loxP/loxP; Psen2–/– mice were injected with cerebral endothelium-specific adeno-
associated control (AAV-BR1-Control; C) or Cre recombinase-expressing (AAV-BR1-Cre; Cre) viruses. b Schematic representation of the qPCR amplicon
used to detect the Psen1 excised allele (orange bar). Right graph: Quantification of the degree of Psen1 excision (a.u., arbitrarty units) in the striatum of C
and Cre mice. Mean ± SEM. n= 3 C and 10 Cre mice; Student’s t-test. c Striatal confocal XY images from C and Cre mice stained with endothelial (IB4; red)
and Psen1 (ISH; brown) markers. Scale bar= 20 µm. d Quantification of endothelial Psen1+ signal in the striatum (left graph) and the cortex (right graph) of
C and Cre mice. Mean ± SEM. n= 4 mice; Student’s t-test. e–g Confocal projections of striatal (e) or hippocampal slices (f, g) from Psen1loxP/loxP; Psen2–/–
mice injected with AAV-BR1-Control or AAV-BR1-Cre viral vectors, and, 2 months later, perfused with Evans blue (EB; white —e) and stained with
endothelial (IB4; red —e, g— or green —f), pericyte (PDGFRß; red —f), astrocytic end-feet (AQP4; green —g), and nuclear (DAPI; blue) markers. Scale
bars= 40 µm. Right graphs are the quantification of: e percentage of area occupied by IB4+ in C and Cre mice in hippocampus (upper row) and striatum
(lower row). Mean ± SEM. n= 3 mice; Student’s t-test. f, g Percentage of area occupied by PDGFRß+ (f) or AQP4+ (g) signal (in distal —D— vessels and
in IB4+ area) in hippocampus form C and Cre mice. Mean ± SEM. n f= 3 C and 5 Cre mice; n g= 4 C and 6 Cre mice ANOVA, post hoc Tukey’s test.
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an antiangiogenic treatment may be able to delay progression of
the disease, a pharmacological intervention to resume the halted
angiogenic activity in AD could be more appropriated.
NPA induces microglia phagocytosis of blood vessels near Aß
plaques. We postulated that the angiogenic cells with halted
differentiation could be eliminated by the activity of other cells
based on (i) the lack of mature markers of endothelial cells
around Aß plaques, (ii) Psen1 excision reached at 19 days after
AAV-BR1-Cre injection was higher than the observed at
60 days, suggesting that the endothelial cells without γ-secretase
activity (those without Psen1) could be removed, and (iii) the
number of Psen1 mRNA foci after viral Cre injection was sig-
nificantly decreased in the cortex (a brain area without VaS
accumulation) whereas only a trend was observed in the
striatum, suggesting that in the later, the cells that lose the
Psen1 allele were either differentiated and lost the expression of
IB4 or were removed. Microglia are the main phagocytic cells in
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generated by deletion of the γ-secretase activity and in those
associated with Aß plaques.
Adult inhibition of endothelial γ-secretase activity induced the
formation of circular cytoplasmic microglial pouches —ball-and-
chain structures characteristic of phagocytic microglia44— that
enveloped IB4+ material (Fig. 6a and Supplementary Movies 2
and 3). Although astrocytic end-feet were decreased in VaS
(Fig. 4g), astrocytic projections could also be involved in the
phagocytosis of endothelial cells. However, we did not observe
any abnormal vascular staining that colocalized with astrocytes
(Supplementary Fig. 7a). Altogether, our data indicate that
induction of NPA is sufficient to disassemble blood vessels and to
induce endothelial cell phagocytosis by microglia.
To study the contribution of microglial phagocytosis to the loss
of Aß plaques-associated blood vessels, we generated a new AD
mouse model where tdTomato was conditionally expressed in the
cytoplasm of endothelial cells (APP-PSEN1/+; Cdh5-Cre::ERT2/+;
tdTomato/+) upon tamoxifen (TMX) treatment. Non-treated
mice did not show any tdTomato staining and blood vessels were
clearly identified in brain sections of TMX-treated WT and APP-
PSEN1/+ mice (Supplementary Fig. 7b). In addition, we also
observed, although with low frequency, tdTomato+ cells extruding
from blood vessels (Fig. 6b and Supplementary Fig. 7c), which
could represent non-terminally differentiated tip/stalk cells.
Interestingly, those cells were found in close apposition to
microglia (Fig. 6b and Supplementary Fig. 7c) and their
projections were total or partially covered by microglial
cytoplasmic extensions (Fig. 6b and Supplementary Fig. 7c). To
confirm that microglia are indeed involved in the local loss of Aß
plaque-associated blood vessels, we first studied the spatial
distribution of microglial and endothelial cells in the absence of
pathology (WT mice) and distal and proximal to Aß plaques in an
AD mouse model. Low magnification images revealed that AßAM
were found covering blood vessels (Fig. 6c, Supplementary Fig. 7d
and Supplementary Movies 4–7), something that was not observed
in WT mice or in microglia distal to Aß deposits (Supplementary
Fig. 7b, d). Quantification of the length of blood vessels covered by
microglia in control and distal areas from Aß plaques in an AD
mouse model revealed no differences (Fig. 6c); however, a clear
increase in coverage was observed around Aß plaques (Fig. 6c).
Finally, we searched for phagocytic pouches similar to those found
in the endothelial secretase inhibition model (Fig. 6a). tdTomato+
microglial pouches were found almost in every Aß plaque
analyzed (Fig. 6d, Supplementary Fig. 7e and Supplementary
Movies 8–10) and in almost all the cases (97%) they were also
reactive for the lysosomal marker CD68 (Fig. 6e), indicating
phagocytic activity.
Altogether, our results indicate that halted angiogenic cells,
without γ-secretase activity or associated with Aß plaques, were
recognized by microglia and removed by phagocytosis (Fig. 6f).
Discussion
Vascular alterations in the AD brain have been linked with the
accumulation of Aß in the wall of blood vessels in the form of
cerebral amyloid angiopathy12 and/or with a direct effect of
extracellular Aß over vascular function45. However, both the
human AD and AD mouse models’ brains (1) show a reduction
in the number of vessels and a debilitation of the BBB around Aß
plaques14–21 and (2) accumulate hypoxic/angiogenic markers
around Aß deposits (see ref. 23 and for recent reviews see12,13),
suggesting an important role of Aß plaques in the continuum of
AD cerebral microvasculature dysfunction and in the induction of
compensatory angiogenesis. We show here that, although
angiogenesis is initiated around Aß plaques, the process is non-
productive leading to the disassembly of Aß plaque-associated
blood vessels and the phagocytic activity of microglia.
The accumulation of extracellular Aß in plaques could alter the
even distribution of brain capillaries producing, together with the
recruitment of innate immune cells, hypoxia-mediated VEGF
expression. Indeed, hypoxia and VEGF accumulates around Aß
plaques23,25–28 and, while some authors proposed that VEGF
could be sequestered in Aß plaques being biologically
unavailable28,29, we observed a high expression of VEGF in
astrocytes surrounding the Aß plaques and an association
between VEGF expression and the protrusion of filopodia from
endothelial cells in mouse models. Notably, we show that the
expression of the angiogenic Iαvß3, an endothelial cell surface
glycoprotein complex and characteristic of VEGF-stimulated
vessels30,46, is associated with Aß plaques, indicating that
angiogenesis is also initiated in the human AD brain around these
deposits.
However, we show here that angiogenesis is non-productive
around Aß plaques, (i) the molecular signature of defective lateral
inhibition34 is enriched in endothelial cells isolated from an AD
mouse model, and (ii) two NPA marker (IB4 and Plaur
mRNA)7–10,34 accumulate in VaS. IB4 is a lectin that binds to
glycoproteins both at the luminal and abluminal sides of endo-
thelial cells and, in the later, it is associated with the basement
membrane that surrounds mature endothelial cells and
pericytes35. During angiogenesis, IB4 is the best histological
marker of tip cells, labeling the full length of angiogenic
filopodia35. Plaur is one of the few genes strongly enriched in tip
cells versus other endothelial cells34 and is involved in the
degradation of the extracellular matrix during angiogenesis47.
IB4+ VaS are probably the result of the angiogenic aperture of the
blood vessels required for the growing of new vascular branches,
involving, among other processes, the loss of the BBB, transient
edema, and destabilization of the basement membrane by the
action of extracellular matrix proteases22. Therefore, the abnor-
mal IB4 staining could be a deposit produced by the pathologic
angiogenesis-mediated basement membrane mobilization.
Fig. 5 Vessels are substituted by vascular scars proximal to Aß plaques. a Left panels, cortical confocal XY images from 8-month-old APP751SL/+ mice
stained with endothelial (IB4; red), red cells (TER119; green), Evens Blue (EB, white), and nuclear (DAPI; blue) markers. Scale bar= 20 µm. Right graphs,
left, quantification of the EB vessel area distal (D) and proximal (P) to Aß plaques. Mean ± SEM. n= 3 mice; Student’s t-test; right, quantification of the
TER119 vessel area in WT, distal (D), and proximal (P) to Aß plaques in APP751SL/+ mice. Mean ± SEM. n= 4 mice; ANOVA, post hoc Tukey’s test. b Left
panels, cortical confocal XY images 8-month-old APP751SL/+ mice stained with vessel basement membrane (laminin, LN; red), endothelial (IB4; white), Aß
(Thio-S; green), and nuclear (DAPI; blue) markers. Scale bar= 20 µm. Right graphs, quantification of the laminin vessel area in WT mice, in distal (D),
proximal (P) to Aß plaques, and inside the IB4+ vascular abnormal structures (IB4+) in 8-month-old APP751SL/+ mice. Mean ± SEM. n= 4 mice; ANOVA,
post hoc Tukey’s test. c Cortical confocal projection 8-month-old APP751SL/+ mice stained with astrocytic end-feet (aquaporin 4, AQP4; green),
endothelial (IB4; cyan), astrocytic (GFAP, red), and nuclear (DAPI; blue) markers. Insets show the white square from low magnification images. Yellow
arrowheads indicate an astrocytic end-feet juxtaposed to an IB4+ structure. Scale bar= 20 µm. Lower graph, left, quantification of the EB vessel area distal
(D) and proximal (P) to Aß plaques. Mean ± SEM. n= 4 WT and 3 APP751SL/+ mice; ANOVA, post hoc Tukey’s test. d Electron microscopy analysis of an
8-month-old APP751SL/+ cortex stained with IB4 (black dots, gold particles). Right image is a high magnification of the left dashed square shown in the left
panel. A yellow asterisk indicates an Aß plaque. Scale bar= 1 µm in low and 0.5 µm in high magnification images.
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Interestingly, NPA induction (γ-secretase genetic inhibition) in
adult endothelial cells is sufficient to produce identical IB4+ VaS
in the absence of amyloid pathology. In the human AD brain, (i)
BBB disruption has been mapped to Aß-depositing areas that
show brain parenchymal accumulation of blood-derived immu-
noglobulin G and Fibrin17, (ii) microhemorrhages are a frequent
characteristic of Aß plaques48, (iii) Aß plaque-associated vascular
ghosts (emanating from blood capillaries) and endothelial debris
have been described using several endothelial basement mem-
brane markers49–53, and (iv) metalloproteases are induced18,
suggesting a similar defective angiogenic process. Under this
arrested angiogenesis, VEGF may also act as permeabilizing fac-
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Could NPA explain the reduced blood vessel density observed
in AD? We postulate that reduction of the lateral inhibition in
angiogenic endothelial cells could disassemble Aß plaque-
associated blood vessels into non-perfused tip cells7–10. How-
ever, tip cells were not easily identified in the brain of an AD
mouse model, suggesting that these cells with halted differentia-
tion could be being removed. Using genetically labeled endothe-
lial cells, we report that microglia strongly react to endothelial
cells in the proximity of Aß plaques and engulf blood vessels
producing phagocytic pouches44. This microglial reaction is
similar to that observed in a mouse model of ischemic cortical
stroke, where microglia were attracted by blood serum proteins
released into the brain parenchyma and engaged in endothelial
cell phagocytosis55,56. The disassembly of pre-exiting blood ves-
sels around Aß plaques could be the consequence of microglial
activation by Aß itself and/or the dysfunction caused by NPA in
endothelial cells. However, γ-secretase genetic inhibition in adult
endothelial cells induced a strong phagocytic phenotype in
microglial cells in the absence of Aß accumulation, strongly
suggesting that NPA induction is sufficient to elicit blood vessels
phagocytosis by microglia. Interestingly, the molecular signature
of reduced lateral inhibition contains, in addition to angiogenic
and tip cell-enriched genes, several inflammatory mediators34
that could induce the cross talk with AßAM. Other interesting
players could be the astrocytes and the non-microglia brain
resident macrophages. Astrocytes produce VEGF around Aß
plaques, accumulate in the deposits, and may have a role in the
degradation of the vessels, either by themselves or by modulating
the phagocytic activity of the microglia. We cannot discard a
possible role of other brain resident macrophages, as actually the
only marker to discern between them and microglia is TMEM119
(ref. 57), which is strongly downregulated in AßAM58. However,
single-cell sequencing in an AD mouse model suggested a minor
role of those cells compared with microglia58 and a recent work
reported that Aß plaque-associated myeloid cells derive from
resident microglia59.
Our results demonstrate that, at least in endothelial cells,
inhibition of the γ-secretase could play a major role in AD
pathology. fAD mutations in PSEN1 and PSEN2 reduce γ-
secretase activity over NOTCH and APP, but increase the ratio
between Aß1–42/Aß1–40 by reducing γ-cleavage following
Aß1–403,4. Owing to the importance of the γ-secretase in the APP
processing, a lot of effort has been made to understand the
consequences of the neuronal loss of γ-secretase activity60,61.
Interestingly, a reduction of only 50% in Dll4 dose (heterozygous
mice) is sufficient to induce NPA7–10, demonstrating the exqui-
site sensitivity of the angiogenic system to subtle changes in the
endothelial NOTCH pathway. Therefore, a vicious cycle can be
perpetuating in AD between accumulation of Aß1–42, an inter-
mediate γ-secretase reaction product that could inhibit its
activity4, and reduction of blood local vessel function by NPA,
which could decrease the local clearance and further stimulate Aß
deposition.
AßAM have a key role in AD progression62–64 and others and
we have recently shown that AD microglia suffer from hypoxic
and metabolic stress that compromise their protective
activity23,65. Therefore, although Aß plaques might constitute an
already late stage in the progression of AD, strategies to rees-
tablish angiogenesis around Aß plaques, including reactivation of
the γ-secretase/NOTCH pathway in endothelial cells, might hold
therapeutic potential.
Methods
Mice. Mice were housed under controlled temperature (22 °C) and humidity
conditions in a 12 h light/dark cycle with ad libitum access to food and water.
Housing and treatments were performed according to the animal care guidelines of
European Community Council (86/60/EEC). Principles of laboratory animal care
(NIH publication No. 86-23, revised 1985) were followed, as well as specific
Spanish national laws where applicable. The competent Spanish authority
approved all the procedures (“Consejería de agricultura, pesca y desarrollo rural.
Dirección general de la producción agrícola y ganadera”). Mice showing any
alterations at the moment of the allocation (wounds, smaller or bigger body size,
etc.) were excluded. B6.Cg-Tg(APPswe,PSEN1Δ9E)85Dbo/J (APP-PSEN1; stock
number 34832-JAX), Cp-HIST1H2BB::Venus/+ (Tg(Cp-HIST1H2BB/Venus)
47Hadj/J; stock number 020942), and Ai14 Cre-reporter mice (B6.Cg-Gt(ROSA)
26Sortm14(CAG-tdTomato)Hze/J; stock number 007914) mice were obtained
from Jackson Laboratories, APP751SL/+ mice66 (Sanofis) were provided by
Transgenic Alliance-IFFA-Credo, Cdh5-Cre::ERT2/+67 was a generous gift from
Prof. Ralf H. Adams and Psen1Floxed and Psen2–/– mice were kindly provided by
Prof. Jie Shen. Only heterozygous APP-PSEN1, APP751SL, Ai14, Cp-HIST1H2BB::
Venus, or Cdh5-Cre::ERT2 mice were used. Experimental groups were homo-
geneously distributed by sex and assigned to each treatment without previous
observation of the mice by the experimenter. No randomization methods were
employed. Mice were euthanized by administration of a lethal dose of anesthesia
(sodium thiopental, thiobarbital). To activate Cre::ERT2-mediated recombination,
mice were fed for 30 days with a diet containing tamoxifen (400 mg tamoxifen
citrate per kg; Envigo). Viral induced Psen1Floxed Cre-mediated recombination in
adult cerebral endothelial cells was achieved by AAV-BR1-Cre40 injection in the
tail vein (5 × 1010 genomic particles per mice). Angiography with Evans Blue was
performed as described35. Sorafenib was injected at a dose of 30 mg/kg/2 day for
30 days. A summary of all the mice used in this article can be found in Supple-
mentary Data 1.
Human samples. The use of brain tissue samples was coordinated by the local
brain bank (Banco de Tejidos CIEN, Madrid, Spain), following national laws and
international ethical and technical guidelines on the use of human samples for
biomedical research purposes. In all cases, brain tissue donation, processing, and
use for research followed published protocols, which include obtaining informed
consent for brain tissue donation from living donors and the approval of the whole
donation process by the Ethical Committee of the Banco de Tejidos CIEN (com-
mittee approval reference 15-20130110). Hippocampal samples included five
samples classified with Braak tau pathology (Braak IV–VI) and five control (Braak
0–I) samples (Supplementary Data 1). For morphological studies, 4%
Fig. 6 Microglial cells phagocyte VaS-associated blood vessels. a Striatal confocal XY images from Psen1loxP/loxP; Psen2–/– mice that were injected with
cerebral endothelium-specific adeno-associated control (AAV-BR1-Control; C) or Cre recombinase-expressing (AAV-BR1-Cre; Cre) viruses, perfused with
Evans blue (EB; white) and stained with endothelial (IB4; red), microglia (IBA1; green), nuclear (DAPI; blue) markers. Yellow arrowheads indicate microglial
IB4+ pouches. Lower row images show the dashed white rectangles depicted in the upper row images. Scale bars= 20 and 10 µm in low and high
magnification images. b–e Cortical confocal images 8-month-old Cdh5-Cre::ERT2/+; R26-LSL-tdTomato/+; APP-PSEN1/+ tamoxifen-treated mice and
stained with a tdTomato antibody (b) or direct tdTomato fluorescence (c–e) (red) and with microglial (IBA1; cyan), astrocytic (GFAP; green —b),
lysosomal (CD68; green—e) and nuclear (DAPI; blue) markers. Aß plaques are indicated with a yellow asterisk. Yellow arrowheads indicate internalization
of tdTomato+ signal by microglial pouches. Lower row images show the dashed white rectangles depicted in the upper row (b, e) or left (c) images. A
white arrowhead indicates a tip cell that projects extensions towards an Aß plaque (b). Scale bars (b–e)= 50 µm in low and 10 µm in high magnification
images. Regions with high alignment of endothelial cells and microglia are highlighted with dashed yellow rectangles in c. Left panel in d shows a z-
projection of a magnified and cropped image from c showing the orthogonal projections and the right panels show different rotated views of 3D
reconstructions of the left image (volume, two central panels; surface, right panel). Right graphs (c–e) show the quantification of c the length of tdTomato+
vessels occupied by IBA1+ signal. Mean ± SEM. n= 3 mice; ANOVA, post hoc Tukey’s test; d the number of microglial pouches proximal to Aß plaques.
Mean ± SEM. n= 3 mice; and e the percentage of microglial IB4+/CD68+ pouches. Mean ± SEM. n= 3 mice. f Working model of the process of vascular
scars (VaS) formation. Numeration continues from Fig. 1f.
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paraformaldehyde fixed samples (24 h) were sectioned (50 µm thickness) on a
vibratome and serially collected in PBS and 0.02% sodium azide33. A summary of
all the human samples used in this article can be found in Supplementary Data 1.
EAE mouse model. Seven-week-old female C57/BL6 mice were purchased from
Charles River Laboratories (Wilmington, MA, USA) and acclimatized for a week in
the appropriate environmental conditions at the Animal Facilities of the Instituto
Cajal-CSIC prior to carrying out the procedure. To induce EAE, we follow the
recommendations of the Spanish Network in Multiple Sclerosis-REEM and the
procedure used in Dr. F. de Castro’s group68. In brief: mice were anesthetized
intraperitoneally with 40 µL of an anesthetic/analgesic mixture containing keta-
mine and xylazine. An emulsion of Myelin Oligodendrocyte Glycoprotein
(MOG35–55 peptide, 250 µg in a final volume of 200 µL; GenScript) and complete
Freund’s adjuvant (CFA) containing inactivated Mycobacterium tuberculosis (4 mg;
BD Biosciences) was induced subcutaneously into groin and armpits. Then, Per-
tussis toxin (400 ng/mouse: Sigma-Aldrich) was intravenously administered in one
of the lateral tail veins. This was also repeated 48 h later. Clinical score in animals
was evaluated until sacrifice by two independent blind observers as follows: 0=
asymptomatic; 0.5= paralysis of the distal tail; 1= loss of muscle tone throughout
the tail; 2=weakness or unilateral partial hindlimb paralysis; 3= bilateral paralysis
of the hind limbs; 4= tetraplegia; and 5= death. Three experimental groups were
organized: “onset” (clinical score ~0.5), “peak” (clinical score between 2.5 and 3),
and “post-peak” (3 days after peak). Animals were sacrificed by intraperitoneal
administration of a lethal dose of pentobarbital and they were perfused transcar-
dially with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB, pH 7.4).
The encephala were obtained and post-fixed overnight in PFA 4% and glutar-
aldehyde 0.025% at room temperature (RT). All procedures were performed in
compliance with the ARRIVE Guidelines, in accordance with the Guidelines of the
European Union (63/2010/EU, 90/219/EEC, Regulation No. 1946/2003) and fol-
lowing the Spanish regulations (RD 53/2013, BOE 8/2(2013) for the use of
laboratory animals. The generation of the EAE murine model of MS at the
Instituto Cajal-CSIC has been properly approved by the institutional and regional
ethics committees (references 2016/049/CEI3/20160411, CSIC440/2016 and
PROEX143/16).
Double ISH and immunohistochemistry (IHC). Mice were euthanized and cer-
ebral samples fixed as in ref. 35. Tissues were cryoprotected in sucrose 30% in PBS
at 4 °C for 24 h and embedded in OCT compound (Tissue-Tek) prior to −80 °C
storage. Thirty-micrometer coronal slices were obtained with a cryostat (Leica) and
stored at −80 °C until use. RNAscope 2.5 Brown (ACD) protocol was used to
detect Vegfa (ACD probe 436961 Vegfa01), Plaur (ACD probe 48731 Plaur), or
Psen1 (ACD probe 451011 Psen1) mRNAs according to the manufacturer’s
instructions for frozen tissue, using a HybEZ oven (ACD). Subsequent immu-
nostaining was performed for microglia (IBA1, 1:200), astrocytes (GFAP, 1:1:500),
EC (IB4; 1:50), Thio-S, and nuclear staining (DAPI). After RNAscope 2.5 Brown
protocol, slices were incubated for 10 min in PBS–0.3% Triton X-100 (v/v) and
washed in PBS. Antibodies were prepared in PBS–0.05% Triton X-100, 2% normal
goat serum (Gibco) and used to incubate the samples overnight at 4 °C. After
several PBS washes, slices were incubated with anti-rabbit conjugated with Alexa-
588 or 647 (Invitrogen, 1:400) for 1 h at room temperature. Several washes with
PBS, Thio-S (0.005% in PBS; 8 min), and DAPI (Sigma, 1:1000; 5 min) were the
final steps before mounting with Fluoromount-G.
Immunodetection. Human brain samples: a protocol adapted from ref. 35 to
human brain samples was used. Briefly, brain sections were incubated in 50 mM
NH4Cl in PBS for 30 min, then in 50 mM glycine in Tris pH 8 for 5 min at 80 °C
with gentle shaking, and finally in CaCl2-containing buffer (0.1 mM CaCl2; 0.1 mM
MgCl2; 0.1 mM MnCl2 diluted in 0.1 M PBS pH 6.8) and heated for 90 s in a
microwave (600W). Sections were incubated for 72 h at 4 °C in blocking solution
(CaCl2-containing buffer, 0.05% (v/v) Triton X-100 and 2% (v/v) NGS in 0.1 M
PBS) using primary antibody (anti-Iαvß3, Abcam, 1:50), secondary antibody
Alexa-568 anti-mouse (Molecular Probes, 1:500), and Thio-S post-staining to
visualize Aß plaques and quantify tangle density. Sections were then treated using
the standard Eliminator (Merck Millipore) protocol and poststained with DAPI
(1:1000). The images were then generated with the NewCAST system (Visiopharm)
associated with the microscope BX61 (Olympus). Mouse samples: mice were
anesthetized with an overdose of thiobarbital and perfused with an intracardial
injection of Evans blue35. The brains were dissected and immediately fixed over-
night at 4 °C with the fixation solution (4% paraformaldehyde in PBS–0.05%
glutaraldehyde). The brains were cryoprotected during 48 h with a solution of 30%
sucrose in PBS and embedded in OCT. Blocks were sliced in 40-μm-thick coronal
sections using a cryostat (CM 1950, Leica). Tissues showing evident technical
alterations (i.e. not properly fixed, stained or cut) were excluded. Immunostaining
was performed on free-floating sections according to the Wälchli et al.35 protocol.
Brain sections were post-fixed in fixation solution and, for antigen unmasking,
sections were incubated in 50 mM NH4Cl in PBS for 30 min, then in 50 mM
glycine in Tris pH 8 for 5 min with gentle shaking at 80 °C, and finally in CaCl2-
containing buffer (0.1 mM CaCl2; 0.1 mM MgCl2; 0.1 mM MnCl2 diluted in 0.1 M
PBS pH 6.8) and heated for 90 s in a microwave (600W). Sections were incubated
for 72 h at 4 °C in blocking solution (CaCl2-containing buffer, 0.05% (v/v) Triton
X-100, and 2% (v/v) NGS in 0.1 M PBS) using primary antibodies (anti-IBA1,
Wako, 1:400; anti-GFAP, Sigma, 1:1000; anti-AQP4 1:5000; anti-TER119, Invi-
trogen, 1:400; anti-mCherry, EnCor Biotechnology, 1:1000—to visualize tdTomato;
and anti-CD68, Bio-Rad, 1:100) or biotinylated IB4 lectin (Sigma, 1:50). For
immunofluorescent studies, we used secondary antibodies anti-mouse or anti-
rabbit conjugated with Alexa-488, Alexa-568, or Alexa-647 (Molecular Probes,
1:800), and streptavidin conjugated with Alexa-488, Alexa-568, and Alexa-647
(Jackson, 1:500). Microwave heating was excluded when anti-Laminin (Sigma,
1:250) and PDGFR-ß (Invitrogen, 1:200), antibodies were employed. Anti-CD31
(BD Biosciences, 1:500) staining was performed in unfixed sections for 1 h, fixed
for 15 min, and the IHC performed as described before. Thio-S (Sigma, 0.005% in
PBS) and DAPI (Sigma, 1:1000) were used as counterstains according to the
standard procedures. Hypoxia staining was performed in three 14-month-old APP-
PSEN1 mice injected intraperitoneally with 60 mg/kg of Pimonidazole HCl and
sacrificed 45 min after injection. Brain was snap frozen in liquid nitrogen, sectioned
in a cryostat (20 µm, Leica), and sections were fixed for 10 min in cold acetone.
Protein–pimomidazole hypoxic adducts were detected using a polyclonal primary
antibody (Hypoxiprobe, 1:50, PAb2627AP) and Aß plaques were counter stained
with Thio-S (green). WT mice injected with pimonidazole HCl and APP-PSEN1
mice without injection were used as negative controls and kidney was used as a
positive control.
Imaging. Unless otherwise stated, all fluorescent images of cortical regions of brain
sections from mouse brains were acquired in a confocal microscope (Nikon A1R+)
in Z-stack series and colocalization images with DAB were performed by
decreasing opacity of the fluorescent images.
Electron microscopy. For EM-gold labeling, 50 µm vibratome sections from APP-
PSEN1/+ mice hippocampus (fixed with 4% paraformaldehyde/75 mM lysine/10
mM sodium metaperiodate) were cryoprotected in a 25% sucrose and 10% glycerol
solution and then frozen at −80 °C in order to increase IB4-lectin-binding effi-
ciency. Sections were incubated in biotinylated IB4 (Sigma, 1:100), followed by 1.4
nm gold-conjugated streptavidin (Nanoprobes, 1:100). The tissue was then post-
fixed in 2% glutaraldehyde and washed in 50 mM sodium citrate. HQ Silver
Enhancement Kit (Nanoprobes) was used and gold-toning was performed. Sections
were then fixed in osmium tetroxide, block-stained with uranyl acetate, dehydrated
in graded acetone, and flat-embedded in Araldite (EMS). Finally, sections were cut
in ultrathin sections (70 nm) and examined under a transmission electron
microscope (JEOL JEM 1400).
Image quantification. Human Integrin/Aß plaques study: we have developed a
method to quantify, measure, and compare the location of integrins and Aβ pla-
ques in two-dimensional images of hippocampus biopsies. This approach consisted
of two steps applied to every biological sample: first, we measured Aβ plaques over
the natural biopsies, and second, we fixed the Aβ plaques positions while rando-
mized the integrins locations over the region of interest (ROI). The ROIs were
defined by the biological sample contained on the image, excluding artefacts and
empty regions. (i) Biopsy measurements: for each integrin marker we have created
a geodesic distance image using the ROI, in which this marker position defined the
origin of coordinates. Then, we captured the chessboard distance assigned to every
pixel position matching with the Aβ plaques markers locations. Thus, we measured
the distance from each integrin marker to the closest Aβ plaque and computed its
average. (ii) Randomizing integrin markers positions: we carried out a randomi-
zation protocol repeated 500 times for each biological sample. We fixed the
integrins markers positions and randomized the Aβ plaques ones along the ROI,
thus we measured the distances between the markers as described above. (iii)
Finally, we compared the minimum distances between integrins and the Aβ pla-
ques obtained in each raw sample and its corresponding 500 randomizations. For
statistical analysis, only ten randomized simulations were used. Area+/cell number
density of different markers: all the measurements were performed in the cortices
of 8-month-old APP-PSEN1/+, APP751SL/+, or WT mice, cortices, striata, and
hippocampi of PSEN1Flox/Flox; PSEN2–/– mice. Cortical XY confocal twin images
(between 5 and 10 images per mice) containing centered Aß plaques (rigorously
scrutinized by Thio-S labeling or blue autofluorescence, when required) and
adjacent brain regions without plaques were used. A circumference of 100 µm of
diameter was drawn in the center of each Aß plaque imaged and the area occupied
by the VaS was also drawn and quantified. Laminin+ areas and Plaur and Psen1
mRNA cell+ number were manually outlined/counted and quantifications were
performed using Fiji (v. 2.0.0). Other markers were measured using a R-based
semi-automatic process to hide the name of the samples and obtain the area
occupied by every marker using Fiji. Quantification of VaS load in AD mouse
models: all the measurements were performed in total cortical area of WT (14-
month-old), APP-PSEN1/+ (8- and 12-month-old), and APP751SL/+ (8-month-
old) mice. Quantifications were done in superimages generated with the NewCAST
system (Visiopharm) associated with the microscope BX61 (Olympus). VaS load
was measured using Fiji. A segmented binary mask was generated and the occupied
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area by detected particles over a specific constant threshold was quantified. Load
was defined as the percentage of total cortical area occupied by VaS. Quantification
of VaS and Plaque areas: all the measurements were performed in total cortical area
of 8- or 12-month-old APP-PSEN1/+ or APP751SL/+ mice. Quantifications were
done in images generated with the upright BX61 microscope (Olympus; ×40
objective). VaS and Thio-S areas were measured using Fiji. A segmented binary
mask was generated and the occupied area by detected particles over a specific
constant threshold was quantified.
Flow cytometry. Mice were anesthetized and transcardially perfused with HBSS
(–CaCl2/–MgCl2) (Gibco) and cortices were dissected and then dissociated using a
Tissue Chopper (Vibratome, 800 series). Chemical digestion was then performed
with a mix of papain (Worthington) (8 U/mL) and DNAse I (Sigma; 80 Kunitz
units/mL) followed by a Percoll gradient (GE Healthcare) at 90% in PBS (v/v). Cells
were stained with primary conjugated monoclonal antibodies CD11b-APC
(eBioscience) and CD31-PE (BD Bioscience) diluted 1:200 at 4 °C for 30 min.
Staining with isotype control-PE and isotype control-APC (eBioscience, 1:200) was
used as a negative control. Both control and experimental samples were simulta-
neously incubated with anti-CD16/CD32 blocker (eBioscience, 1:200). Cells were
washed and sorted using a FACS Aria Fusion (Becton Dickinson) flow cytometer
and data acquired and analyzed with FACSDiva software 8.0 (Becton Dickinson).
Gating strategy and data analysis were done according to the guidelines69. Debris
and dead cells were discarded by forward and side scatter pattern. FSC-A and FSC-
H events distribution was used to gate single cells (Supplementary Fig. 2). Endo-
thelial cells were identified as positive events for CD31 and negative for CD11b.
Percentages are relative to total single cells.
DNA and RNA extraction and quantitative reverse transcriptase (qRT)-PCR
and qPCR
FACS-isolated endothelial cells and mouse brain samples. RNA was extracted from
FACS-isolated endothelial cells using TRIzol reagent (Life Technologies) and DNA
from mouse brain areas using DirectPCR (Viagen). RNA samples (full RNA
extracted from isolated cells) were treated with PerfeCTa DNase (Quanta Bios-
ciences) and copied to cDNA using qScript cDNA Supermix (Quanta Biosciences).
Real-time q(RT)-PCR was performed for all samples in a ViiA 7 Real-Time PCR
System (Applied-Biosystems) using Power SYBR-Green PCR Master Mix
(Applied-Biosyor iTaq Universal Probes Supermix, Bio-Rad) (Primers: Cdh5: 5′-
TCTCTGCAACAGACAAGGATGTG-3′, 5′-TGTTGGCGGTGTTGTCATG-3′;
Cd33: 5′-GAGGCAGGAAGCGATCACAT-3′; 5′-GTGTATGGAACATCCTGG
AGTCAC-3′; Gfap: 5′-GCCACCAGTAACATGCAAGAGA-3′; 5′-TGCAAACTT
AGACCGATACCACTC-3′; Gstp1: 5′-ATGCCACCATACACCATTGTC-3′; 5′-G
GGAGCTGCCCATACAGAC-3′; Hmbs: 5′-CCATACTACCTCCTGGCTTTACT
ATTG-3′; 5′-GGTTTTCCCGTTTGCAGATG-3′; Iba1: 5′-ATCAACAAGCAAT
TCCTCGATGA-3′; 5′-CAGCATTCGCTTCAAGGACATA-3′; Psen1: 5′-TGAGC
CAATTCAAGCCAGAGT-3′; 5′-TGTGTGTGGTCTGTGAAGAGT-3′; Stt: 5′-AC
CGGGAAACAGGAACTGG-3′; 5′-TTGCTGGGTTCGAGTTGGC-3′; Stnb2: 5′-A
ACACCTTGATCTTACGCTGCAA-3′; 5′-GCCTCCCGCTGTACTGGTT-3′).
Microarray. The RNA quality was analyzed using an Agilent 2100 Bioanalyzer
(Agilent). Only samples with RNA integrity number (RIN) higher than 7 were
further processed for microarray analysis. RNA was amplified and labeled using the
GeneChip WT Pico Reagent Kit (the total RNA isolated was used as the starting
material; Affymetrix). The amplified cDNA was quantified, fragmented, and
labeled in preparation for hybridization to GeneChip® Mouse Transcriptome 1.0
Array (Affymetrix) using 5.5 μg of single-stranded cDNA product and following
protocols outlined in the user manual. Washing, staining (GeneChip® Fluidics
Station 450, Affymetrix), and scanning (GeneChip® Scanner 3000, Affymetrix)
were performed following the protocols outlined in the user manual for cartridge
arrays. Raw data from the extraction software Expression Console (Affymetrix)
were imported to the R statistical processing environment (RStudio, Inc.) using the
LIMMA/Bioconductor package. Quality of the data was assessed using Array
Quality Metrics package. Data were normalized using the Robust Multi-Array
(RMA) method and differential expression analysis was done using LIMMA/Bio-
conductor package. The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible through GEO Series acces-
sion number GSE97423. A list of the DE genes in the retina of Dll4+/– mice34 was
obtained from their authors. To identify underlying biological processes in endo-
thelial cells from APP-PSEN1/+ mouse models, we used GSEA. We analyzed the
enrichment of 825 gene sets from the Biological Processes Database C5 version 5.1
and the custom GS Dll4+/–_Up (50 most upregulated genes—FDR p < 0.05—in
ref. 34).
iDISCO. Brains from WT and APP-PSEN1/+ mice were clarified following the
iDISCO protocol70 with some modifications. Brains were consecutively perfused
with PBS-Evans blue and the fixation solution (4% paraformaldehyde in
PBS–0.05% glutaraldehyde). Samples were not treated with methanol to preserve
IB4 staining, blocked for 3 days at 37 °C, and both the wash solution and the
primary antibody solution were prepared using CaCl2-containing buffer, to
improve the filopodia and endothelial cell staining. The brains were incubated in
IB4 (Sigma, 1:50) for 3 days at 37 °C and a Cy3 conjugated streptavidin (Jack-
son, 1:500) was used for 3 days at 37 °C. In all incubation steps azide 0.02% was
included to avoid contamination. For nuclear labeling, immunolabeled samples
were incubated with DAPI (1:1000 in PBS–0.2% Tween–20; 10 μg/mL heparin).
For brain clarification, samples were incubated overnight in 10 mL of 50% v/v
tetrahydrofuran–H2O (THF; Sigma), 10 mL of 80% THF–H2O for 1 h, twice in
100% THF for 1 h, and then in dichloromethane (Sigma) until samples sank at the
bottom of the vial. Finally, samples were incubated in 18 mL of dibenzyl ether
(DBE, Sigma) until clear (2 h) and then stored in DBE at room temperature.
iDISCO imaging and image processing. Three-dimensional (3D) imaging of
brain samples was performed with a bidirectional light sheet microscope (Ultra-
microscope II, LaVision BioTec), controlled by the ImspectorPro Software
(LaVision BioTec), with a stereomicroscope (MVX10, Olympus, Japan) equipped
with a ×2 objective (MVPLAPO, Olympus). Images were acquired using a Neo
sCMOS camera (Andor, Oxford Instruments) at a magnification of ×0.8, ×1.6, and
×6.3, with the tissue submerged in Ethyl Cinnamate. Cy3 was excited with laser line
561 nm and collected with a BP 620/60 filter. To avoid saturated pixels, laser
intensities were set at 4–6%. The numerical aperture of the light sheet was set at
0.078, so the step size was fixed at 2 µm. Imaris software (Bitplane, http://www.
bitplane.com/imaris/imaris) was used to generate 3D volume and movie files, using
the volume rendering function and the snapshot and animation tools.
Statistics and reproducibility. All individual measurements constitute indepen-
dent biological replicates and the experiments were repeated at least three times
(for quantifications, the n is specified in the figure legends). Samples with an n < 9
were analyzed using parametric tests. Samples with an n ≥ 9 were evaluated for
normal distribution using the D’Agostino and Pearson’s omnibus normality test.
Comparisons between two groups were performed with two-sided unpaired Stu-
dent’s t-test, whereas comparisons between more than two groups were done with
ANOVA with Tukey’s test. Data not adjusting to a normal distribution were
analyzed using non-parametric test (Kruskal–Wallis test followed by Dunn’s
multiple comparison test). Data expressed as mean ± SEM; p ≤ 0.05 were con-
sidered statistically significant. Statistical analyses and graphs were performed in
GraphPad Prism version 6.0 (GraphPad Inc.).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw data of endothelial cells microarray are available at the Gene Expression
Omnibus under accession code GSE121729. Source data are provided with this paper.
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